Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Self-reported incidence and age of onset of chronic comorbid medical conditions in adults aging with long-term physical disability.
Overview of treatment options in multiple sclerosis.
Subcutaneous interferon β-1a in pediatric patients with multiple sclerosis: Regional differences in clinical features, disease management, and treatment outcomes in an international retrospective study.
Oral Agent Outcomes
Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy.
The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients.
Effect of wearing a dorsiflexion assist orthosis on mobility, perceived fatigue and exertion during the six-minute walk test in people with multiple sclerosis: a randomised cross-over protocol.
In vitro assessment of the direct effect of laquinimod on basic functions of human neural stem cells and oligodendrocyte progenitor cells.
Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.
DYNACIN (MINOCYCLINE)
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
Wnt Signaling in the Pathogenesis of Multiple Sclerosis-Associated Chronic Pain.
Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications
Diffusion Tensor Imaging (DTI) - A New Imaging Technique Applyed in Multiple Sclerosis.
NAD⁺ in aging, metabolism, and neurodegeneration.
Immune surveillance in multiple sclerosis patients treated with natalizumab.
Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions.
Rehabilitation in transverse myelitis.
Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
Extension Trial Data Shows Cladribine Benefits Persist in RRMS Patients
Sativex(®) in multiple sclerosis spasticity: a cost-effectiveness model.
Effects of functional electrical stimulation on gait function and quality of life for people with multiple sclerosis taking dalfampridine.
The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
Can we overcome the 'clinico-radiological paradox' in multiple sclerosis?

Pages